Burcu GENÇ, Ayşe ÖZKAN, İbrahim BAYRAM, Gülay SEZGİN, Serhan KÜPELİ, Atila TANYEL, İ

Çocukluk çağında akut lösemi tanısı alan hastaların sonuçları ve akım sitometri ile değerlendirilmesi

Amaç: Bu çalışmada; çocukluk çağı akut lösemi hastalarının sonuçlarının ve akım sitometri sonuçlarının değerlendirilmesi, prognoz ve diğer klinik durumlar ile ilişkisinin araştırılması planlandı. Gereç ve Yöntem: Bu çalışmaya, Ocak 2008 ile Kasım 2013 arasında hastanemizde tanı alan 69 akut lenfoblastik lösemi (ALL) ve 24 akut miyeloid lösemi (AML) hastası olmak üzere toplam 93 hasta dahil edildi. Bulgular: Çalışmamızda, ALL hastalarında 5 yıllık genel sağkalım (OS) % 66, AML hastalarında ise % 80 saptandı. Lösemi hastaları, akım sitometrik olarak yüzey antijenlerine (CD) göre sınıflandırıldığında; CD2(+) hastalarda 5 yıllık OS % 77, CD2(-) hastalarda ise % 58 idi. CD10(+) hastalarda, 5 yıllık OS % 82, CD10(-) olan hastalarda ise % 61 idi. Ancak, sonuçlar istatistiksel olarak anlamlı değildi (p>0.05). ALL hastaları, T ve B hücre belirteçleri pozitif ALL olarak iki gruba ayrılarak değerlendirildi; T hücre belirteçleri pozitif ALL hastalarının 5 yıllık OS’leri, B hücre belirteçleri pozitif ALL hastalarına göre daha düşük saptandı (sırasıyla % 59 ve % 75) (p=0.518). AML hastaları ise lenfoid belirteçleri pozitif ve negatif AML olarak iki gruba ayrıldı, lenfoid belirteçleri pozitif AML hastalarının 5 yıllık OS’leri, lenfoid belirteçleri negatif olanlara göre daha yüksek saptandı (sırasıyla % 83 ve %70) (p=0.638). Bu sonuçlar istatistiksel olarak anlamlı değildi. Sonuç: Lösemi hastalarımızın akım sitometri ile değerlendirilmesinde, CD10(+) olan hastaların 5 yıllık OS’lerinin daha iyi olduğu, CD2(+) olan hastalarda ise daha düşük olduğu saptandı. ALL hastalarında B hücre belirteçleri pozitif hastaların, AML hastalarında ise lenfoid belirteçleri pozitif hastaların sonuçları daha iyi idi.

Flow cytometric evaluation and outcomes of pediatric acute leukemia patients

Purpose: In this study, the outcomes and flow cytometry results of childhood acute leukemia patients and their relationship with the prognosis and other clinical conditions was investigated. Materials and Methods: A total of 93 patients, including 69 acute lymphoblastic leukemia (ALL) and 24 acute myeloid leukemia (AML) patients diagnosed at our hospital between January 2008 and November 2013, were included. Results: 5-year overall survival (OS) was 66% in ALL patients and 80% in AML patients. When leukemia patients were classified flow cytometrically according to their cell surface antigens (CD); 5-year OS was 77% in CD2(+) patients and 58% in CD2(-) patients. Five-year OS was 82% in patients with CD10(+) and 61% in patients with CD10(-). However, the results were not statistically significant (p>0.05). ALL patients were divided into two groups as ALL with positive T cell markers and ALL with positive B cell markers in the foreground and evaluated accordingly, and the OS of ALL patients with positive T cell markers in the foreground was lower than ALL patients with positive B cell markers in the 5 year (59% and 75%, respectively) (p =0.518). On the other hand, AML patients were divided into two groups as AML with positive lymphoid markers and AML with negative lymphoid markers, and the 5 year OS of AML patients with positive lymphoid markers was higher than AML patients with negative lymphoid markers (83% and 70%, respectively) (p = 0.638). These results were not statistically significant. Conclusion: In the flow cytometric evaluation of our patients with leukemia, it was found that patients with CD10(+) had a better 5-year OS and patients with CD2(+) had a lower 5-year OS. The results of patients with positive B cell markers were better in ALL patients, and the results of patients with positive lymphoid markers were better in AML patients.

Keywords:

acute leukemia, flow cytometry, prognosis,

PDF

___

1. McKenney AH, Cleary ML, Arber DA. Pathology and Molecular Diagnosis of Leukemias and Lymphomas. In: Pizzo PA, Poplack DG, Eds. Principles and Practice of Pediatric Oncology, 7th ed. Philadelphia: Wolters Kluwer. 2016;113-30.
2. Rabin KR, Gramatges MM, Margolin JF, Poplack DG. Acute Lymphoblastic Leukemia. In Pizzo PA, Poplack DG, Eds. Principles and Practice of Pediatric Oncology, 7th ed. Philadelphia: Wolters Kluwer. 2016;463-97.
3. Arceci RJ, Meshinchi S. Acute Myeloid Leukemia and Myelodysplastic Syndromes. In: Pizzo PA and Poplack DG, Eds. Principles and Practice of Pediatric Oncology, 7th ed. Philadelphia: Wolters Kluwer. 2016;498-544.
4. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the acute leukaemias. FrenchAmerican-British (FAB) co-operative group. Br J Haematol 1976, 33:451–8.
5. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A et al. Proposals for the immunological classification of acute leukaemias. Leukaemia 1995;9:1783–6.
6. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. 2008; IARC Press, Lyon, France.
7. Leach M, Drummond M and Doig A. Acute Leukemia In: Leach M, Drummond M and Doig A Eds. Practical Flow Cytometry in Haematology Diagnosis, First ed. Wiley. 2013;43-93.
8. Bain BJ, Barnett D, Linch D, Matutes E, Reilly JT. Revised guideline on immunophenotyping in acute leukaemias and chronic lymphoproliferative disorders. Clin Lab Haematol. 2002;24:1–13.
9. Yan L, Ping N, Zhu M, Sun A, Xue Y, Ruan C et al. “Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO2008 classification’’. Haematologica. 2012;97:1708-12.
10. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with b-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115:3206-14
11. Bayram I, Erbey F, Kömür M, Tanyeli A. Total parenteral nutrition and decreased dose idarubicin based treatment of acute myeloid leukemia during childhood. Eur J Gen Med. 2010;7:282-87.
12. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350:1535–48.
13. Ward E, Desantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014.
14. Ishii E, Eguchi H, Matsuzaki A, Koga H, Yanai F, Kuroda H et al. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors. Med Pediatr Oncol. 2001;37:10- 19.
15. Hastings C, Gaynon PS, Nachman JB, Sather HN, Lu X, Devidas M et al. Increased post induction intensification improves outcome in children and adolescents with a markedly elevated White blood cell count (>200 × 109/L) with T cell Acute Lymphoblastic Leukemia but not B-cell disease: a report from the Children’s Oncology Group. Br J Haematol. 2015;168:533-46.
16. Stiller CA, Parkin DM. Geographic and ethnic variations in the incidence of childhood cancer. British Medical Bulletin. 1996;52:82-703.
17. Ratei R, Schabath R, Karawajew L, Zimmermann M, Möricke A, Schrappe M et al. Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial. Klin Padiatr. 2013;225:34-9.
18. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30:1663-9.
19. Clarke RT, Van den Bruel A, Bankhead C, Mitchell CD, Phillips B, Thompson MJ. Clinical presentation of childhood leukaemia: a systematic review and metaanalysis. Arch Dis Child. 2016;101:894-901
20. Margolin JF, Steuber CP, Poplack DG. Acute lymphoblastic leukemia. In Pizzo PA, Poplack DG, Eds. Principles and Practice of Pediatric Oncology, 4th ed. Philadelphia: Lippincott Williams- Wilkins. 2001:489-544.
21. Riehm H, Gadner H, Henze G. The Berlin childhood acute lymphoblastic leukemia therapy study, 1970- 1976. Am J Pediatr Hematol Oncol. 1980;2:299.
22. Campbell M, Castillo L, Riccheri C, Janic D, Jazbec J, Kaiserova E et al. A randomized trial of the I- BFMSG for the management of childhood non- b acute lymphoblastic leukemia, ALL IC-BFM 2009- Trial Steering Committee. 2009;1-191.
23. Raetz EA, Bhatla T. Where do we stand in the treatment of relapsed acute lymphoblastic leukemia? Hematol Am Soc Hematol Educ Program. 2012;2012:129-36.
24. Hunger SP, Loh ML, Whitlock JA, Winick NJ, Carroll WL, Devidas M et al. Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60:957.
25. Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int. 2018;60:4.
26. Rubnitz JE, Razzouk BI, Lensing S, Pounds S, Pui CH, Ribeiro RC. Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer. 2007;109:157-63.
27. Liang DC, Chan TT, Lin KH, Lin DT, Lu MY, Chen SH et al. Improved treatment results for childhood acute myeloid leukemia in Taiwan. Leukemia. 2006;20:136-41.
28. Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG. Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. J Clin Oncol. 2005;23:9172-8.
29. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer Statistics,2008. CA Cancer J Clin. 2008;58:71-96.
30. Şaşmaz İ, Tanyeli A, Bayram İ, Antmen B, Yılmaz L, Küçükosmanoğlu O, Kılınç Y. The results of treatment with idarubicin in childhood acute nonlymphoblastic leukemia. Turkish Journal of Pediatrics. 2004;46:32-7.
31. Peters JM, Ansari MQ. Multiparameter flow cytometry in the diagnosis and management of acute leukemia. Arch Pathol Lab Med. 2011;135:44-54.
32. Bhojwani D, Yang JJ, Pui CH. Biology of childhood acute lymphoblastic leukemia. Pediatr Clin North Am. 2015;62:47.
33. Ding B, Zhou L, Jiang X, Li X, Zhong Q, Wang Z et al. The Relationship between Clinical feature, complex immunophenotype, chromosome karyotype, and outcome of patients with acute myeloid leukemia in China. Dis Markers. 2015;2015:382186.